

# Zongmei Zhou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6384500/publications.pdf>

Version: 2024-02-01

63  
papers

1,113  
citations

430754

18  
h-index

477173

29  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1293  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2021, 7, 1178.	3.4	128
2	Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis. <i>Frontiers in Oncology</i> , 2019, 9, 269.	1.3	99
3	Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. <i>Cancer</i> , 2011, 117, 5423-5431.	2.0	76
4	Risk Factors for Brain Metastases in Locally Advanced Non-Small Cell Lung Cancer With Definitive Chest Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 330-337.	0.4	59
5	Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma. <i>Annals of Thoracic Surgery</i> , 2014, 98, 513-519.	0.7	46
6	Prediction of Radiation Pneumonitis With Dose Distribution: A Convolutional Neural Network (CNN) Based Model. <i>Frontiers in Oncology</i> , 2019, 9, 1500.	1.3	40
7	The Impact of Postoperative Conformal Radiotherapy After Radical Surgery on Survival and Recurrence in Pathologic T3N0M0 Esophageal Carcinoma: Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1143-1151.	0.5	35
8	Deep Learning Improved Clinical Target Volume Contouring Quality and Efficiency for Postoperative Radiation Therapy in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1192.	1.3	35
9	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1565-1573.	0.5	32
10	Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy. <i>Oncologist</i> , 2016, 21, 1530-1537.	1.9	30
11	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2890-2898.	0.7	28
12	Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 144.	1.1	28
13	A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1718-1724.	0.7	25
14	Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases. <i>BMC Cancer</i> , 2015, 15, 715.	1.1	24
15	Postoperative Radiotherapy in Pathological T2-N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. <i>Oncologist</i> , 2020, 25, e701-e708.	1.9	23
16	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. <i>Radiation Oncology</i> , 2019, 14, 106.	1.2	22
17	Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution. <i>Thoracic Cancer</i> , 2015, 6, 399-406.	0.8	21
18	A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. <i>Radiation Oncology</i> , 2019, 14, 48.	1.2	20

#	ARTICLE	IF	CITATIONS
19	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants. <i>JAMA Network Open</i> , 2019, 2, e1918070.	2.8	17
20	Clinical outcomes and radiation pneumonitis after concurrent EGFR tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 814-823.	0.8	17
21	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. <i>Radiotherapy and Oncology</i> , 2019, 140, 159-166.	0.3	16
22	A deep learning method for producing ventilation images from 4DCT: First comparison with technegas SPECT ventilation. <i>Medical Physics</i> , 2020, 47, 1249-1257.	1.6	16
23	Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma. <i>Thoracic Cancer</i> , 2015, 6, 597-604.	0.8	15
24	MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	15
25	Postoperative Adjuvant Therapy Versus Surgery Alone for Stage II-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. <i>Oncologist</i> , 2021, 26, e2151-e2160.	1.9	15
26	Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. <i>Acta Oncologica</i> , 2021, 60, 627-634.	0.8	13
27	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage II-III thoracic esophageal squamous cell carcinoma after esophagectomy. <i>Oncotarget</i> , 2016, 7, 55211-55221.	0.8	13
28	Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2017, 12, 195.	1.2	12
29	A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer – the 3JECROG P-01 study protocol. <i>BMC Cancer</i> , 2019, 19, 397.	1.1	12
30	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. <i>Journal of Cancer</i> , 2019, 10, 1985-1990.	1.2	11
31	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. <i>Oncotarget</i> , 2017, 8, 41102-41112.	0.8	10
32	Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study. <i>Thoracic Cancer</i> , 2019, 10, 1431-1440.	0.8	10
33	A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-II/III esophageal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 130.	1.1	10
34	S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. <i>Frontiers in Oncology</i> , 2020, 10, 1499.	1.3	9
35	Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial. <i>Radiation Oncology</i> , 2020, 15, 155.	1.2	9
36	Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 53-60.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China. <i>Radiation Oncology</i> , 2021, 16, 102.	1.2	8
38	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. <i>BMC Cancer</i> , 2020, 20, 901.	1.1	7
39	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. <i>BMC Cancer</i> , 2020, 20, 278.	1.1	7
40	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 244-250.	0.3	7
41	The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC). <i>Oncotarget</i> , 2017, 8, 48922-48929.	0.8	7
42	Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution. <i>Annals of Surgical Oncology</i> , 2022, 29, 4408-4416.	0.7	7
43	Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. <i>Tumori</i> , 2020, 107, 030089162096798.	0.6	6
44	Managing a radiotherapy center safely and efficiently using risk-adaptive strategies during coronavirus disease pandemic: Experience from national cancer center of China. <i>Radiation Oncology</i> , 2020, 148, 243-244.	0.3	6
45	CHST15 promotes the proliferation of TEAC1 cells via multiple pathways in esophageal cancer. <i>Oncology Reports</i> , 2020, 43, 75-86.	1.2	6
46	Treatment outcomes of patients with stage III non-small cell lung cancer and interstitial lung diseases receiving intensity-modulated radiation therapy: A single-center experience of 85 cases. <i>Thoracic Cancer</i> , 2022, , .	0.8	5
47	Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. <i>Thoracic Cancer</i> , 2019, 10, 799-806.	0.8	4
48	Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 7076-7086.	0.7	4
49	Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis. <i>Thoracic Cancer</i> , 2021, 12, 1831-1840.	0.8	4
50	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. <i>Lung Cancer</i> , 2021, 157, 116-123.	0.9	4
51	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 781340.	1.3	4
52	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma. <i>Radiation Oncology</i> , 2022, 17, 58.	1.2	4
53	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. <i>Thoracic Cancer</i> , 2022, 13, 296-307.	0.8	4
54	Radiation pneumonitis complicated by <i>Pneumocystis carinii</i> in patients with thoracic neoplasia: a clinical analysis of 7 cases. <i>Cancer Communications</i> , 2019, 39, 1-4.	3.7	3

#	ARTICLE	IF	CITATIONS
55	Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic Carcinoma. Thoracic and Cardiovascular Surgeon, 2020, 68, 440-445.	0.4	3
56	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110619.	1.4	3
57	Primary intrathoracic liposarcoma: a clinical analysis of 31 cases. Cancer Communications, 2019, 39, 1-3.	3.7	2
58	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210803.	0.6	2
59	<p>Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study</p>. Cancer Management and Research, 2020, Volume 12, 9643-9653.	0.9	1
60	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. BMC Cancer, 2020, 20, 877.	1.1	1
61	Prospective Exploratory Study of the Clinical Significance of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Exposed to Prophylactic Cranial Irradiation. Frontiers in Oncology, 2020, 10, 575394.	1.3	1
62	Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis. Frontiers in Oncology, 2021, 11, 618776.	1.3	1
63	Factors affecting the completion of concurrent chemotherapy and impact of non-completion on survival in locally advanced esophageal squamous cell carcinoma. Esophagus, 0, , .	1.0	1